Comment by Veserv

Yes? I meant they should be allowed to run independent clinical trials and then submit for approval.

I also did point out that the integral nature of the manufacturing process is a obvious potential problem. It, however, does not seem like a insurmountable problem. The specifications on sourced components and the quality control processes applied to them is already integral to the drug manufacturing process. This would just move it one level further up where the final drug produced by some existing production process is a “component”. They also already approve drugs for different uses and evaluate existing drugs for new uses, so it does not seem that qualitatively different from some existing approval procedures. I am not sure of the exact details and am not proposing a specific solution, but it certainly does not seem to be a deal breaker.